Sienna Cancer Diagnostics Ltd. has entered into a research collaboration agreement with Minomic International Ltd, to develop a proprietary test for the early detection of pancreatic cancer. This will be the first application of Sienna's capture technology that was acquired in April 2019. The general capture technology is trademarked as SIEN-NETTM and the specific exosome capture technology as EXO-NETTM. Sienna will provide EXO-NET beads which rapidly and specifically capture exosomes (nanoparticles shed from cells into the bloodstream) from blood and other body fluids. Several independent studies have indicated that exosomes from pancreatic cancer patients contain a protein called glypican-1 (GPC-1). Minomic holds a strong intellectual property position around GPC- 1 with four families of patents already completing Patent Cooperation Treaty applications. Based on the data, the companies have agreed to enter into a collaboration to conduct research to determine the feasibility of producing an assay for the accurate screening, diagnosis and prognosis of pancreatic cancer.